{"doi":"10.1001/jamanetworkopen.2021.22326","title":"Allergic Reactions After COVID-19 Vaccination—Putting Risk Into Perspective","abstract":"Israel initiated a successful national vaccination program with the Pfizer-BioNTech mRNA SARS-CoV-2 vaccine. Shavit et al 1 conducted an 8-week prospective cohort study in which they risk stratified potentially allergic patients into low-risk and high-risk groups prior to vaccination. Patients considered to be at higher risk (or highly allergic) were monitored at a single specialty center for 2 hours after vaccination, while those considered to be at low risk of allergic reactions would undergo the regular protocol of 30-minute monitoring after vaccination in the routine setting. Interestingly, the low-risk allergy groups included many of those overrepresented in anaphylaxis reports in the Centers for Disease Control and Prevention's Vaccine Adverse Event Reporting System (VAERS) 2 : those who had chronic urticaria; sensitivity to foods, venoms, or aeroallergens; or nonanaphylactic reactions to drugs or contrast media. Patients at high risk for allergic reactions were those with a history of mast cell disorders, multiple drug allergies, multiple allergies, or a history of anaphylaxis to a drug or vaccine as well as those for whom their primary physician, allergist, or immunization team did not feel comfortable vaccinating in the routine setting.","journal":"JAMA Network Open","year":2021,"id":202783,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":6,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9604,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":106289,"name":"Elizabeth J. Phillips","orcid":"0000-0002-7623-3383","position":0,"is_corresponding":true}],"reference_count":8,"raw_metadata":null,"created_at":"2026-07-18T23:51:10.291262Z","pmid":"34463751","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}